2020 Drug Safety Communications
Current Drug Safety Communications More Drug Safety Communications
- 10-15-2020: FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid
- 9-24-2020: FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)
- 9-23-2020: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class
- 8-26-2020: FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
- 7-23-2020: FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder
- 4-24-2020: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
- 3-4-2020: FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis
- 2-13-2020: FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
- 1-28-2020: FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems
- 1-14-2020: Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)